Goal 3: Advance Translational Research

Modulating Immune Checkpoints to Enhance Curative Potential of Autologous Transplantation in classical Hodgkin lymphoma (cHL)

PD-L1 and PD-L2, engage PD-1 receptors on activated T cells and induce T-cell exhaustion. Antibody-mediated PD-1 blockade has already been successfully exploited as a therapeutic strategy in solid tumors. PD-L1 is expressed on suppressor immune cells in the tumor microenvironment and in cHL tumors. PD1 blockade has shown clinical activity in cHL. Disease relapse, post autoHCT; however remains the most common cause of therapy failure. Prevention of disease relapse post autoHCT in relapsed cHL is an area of unmet need.The post autoHCT setting is a particularly attractive context for PD-1 blockade. This is a state of low-volume residual disease, during which there is a remodeling of the immune system. Can PD-1 pathway enhance curative of HCT?

Tags (Keywords associated with the idea)


26 net votes
46 up votes
20 down votes
Idea No. 573